 Bicycle Therapeutics plc NASDAQ:BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycles technology, today reported financial results for the fourth quarter and full year ended December 31, 2019 and discussed recent corporate updates. 